NYSE · TMO
Healthcare · Medical - Diagnostics & Research
$651.45
Down-$6.87 (-1.04%)
Updated Sep 21, 2026, 10:46 AM
SID Score
6.8/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
TMO closed at $651.45 after 19 trading sessions, up 3.61% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $656.61 | $660.10 | $646.805 | $651.45 | 4.58M |
| Sep 17, 2026 | $656.75 | $663.57 | $649.00 | $658.32 | 4.2M |
| Sep 16, 2026 | $642.00 | $653.40 | $638.00 | $648.43 | 2.88M |
| Sep 15, 2026 | $615.47 | $641.97 | $613.95 | $641.39 | 3.02M |
| Sep 14, 2026 | $614.94 | $616.00 | $605.65 | $613.62 | 1.27M |
| Sep 11, 2026 | $609.96 | $615.24 | $606.15 | $609.82 | 1.79M |
| Sep 10, 2026 | $596.47 | $606.63 | $594.82 | $603.18 | 1.55M |
| Sep 9, 2026 | $601.93 | $609.51 | $597.31 | $605.69 | 1.96M |
| Sep 8, 2026 | $602.20 | $608.10 | $595.82 | $603.02 | 2.7M |
| Sep 4, 2026 | $608.58 | $615.74 | $605.525 | $613.78 | 1.23M |
| Sep 3, 2026 | $614.03 | $622.91 | $603.52 | $618.43 | 1.8M |
| Sep 2, 2026 | $601.63 | $614.5975 | $600.70 | $608.54 | 1.62M |
| Sep 1, 2026 | $619.00 | $621.00 | $599.52 | $600.50 | 1.39M |
| Aug 31, 2026 | $614.38 | $620.715 | $610.35 | $617.10 | 1.43M |
| Aug 28, 2026 | $626.58 | $630.00 | $617.45 | $622.18 | 1.02M |
| Aug 27, 2026 | $629.47 | $637.13 | $626.33 | $630.70 | 1.47M |
| Aug 26, 2026 | $622.23 | $636.06 | $622.23 | $633.71 | 1.84M |
| Aug 25, 2026 | $631.01 | $647.00 | $618.0303 | $628.15 | 1.54M |
| Aug 24, 2026 | $630.00 | $630.00 | $615.97 | $628.74 | 1.73M |
The latest Smart Investors Daily articles mentioning TMO.
TMO research
Company profile and research snapshot.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 3, 2026 | CLSA | Outperform | — |
| Jul 27, 2026 | Morgan Stanley | Overweight | — |
| Jul 27, 2026 | Piper Sandler | Neutral | — |
| Jul 24, 2026 | Barclays | Overweight | — |
| Jul 24, 2026 | RBC Capital | Sector Perform | — |
No generated briefing is available yet.
Yahoo · Sep 18, 2026
Life sciences solutions and products provider Thermo Fisher Scientific (NYSE:TMO)’s shares have done well in September and are up by more than 8% since the 10th. On the 15th, Cramer discussed the strength in the shares in a conversation with his co-host David Faber amidst the turmoil in the AI sector on the back of […]
Yahoo · Sep 18, 2026
Fenimore Asset Management, an investment management company, released its Q2 2026 investor letter. You can download the letter here. U.S. equity markets saw broad gains in Q2, driven by strong corporate earnings, economic resilience, and enthusiasm for artificial intelligence (AI). Major indices reached all-time highs, though the energy sector declined. Continued earnings growth, especially among […]
Yahoo · Sep 18, 2026
AI, Advanced Sequencing and Precision Medicine Drive Genomics Opportunities Across Diagnostics, Drug Development and Preventive CareDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Genomics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Genomics Market Forecast to Reach USD 188.7 Billion by 2035, Driven by Precision Healthcare and Sequencing Innovation The global genomics market was valued at USD 44.7 bi
Yahoo · Sep 18, 2026
Pharmacogenomics Expands as Multi-Gene Testing, Bioinformatics and Precision Diagnostics Drive Clinical AdoptionDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Pharmacogenomics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Pharmacogenomics Market to Reach USD 15.4 Billion by 2035, Driven by Precision Medicine Adoption The global pharmacogenomics market was valued at USD 5.7 billion in 2025 and is proje
Interpretive context generated from the platform’s current data sources.
Thermo Fisher Scientific Inc. shares closed at $651.45, reflecting a daily decline of approximately 1.05%, per SID market data. Despite the session's pullback, the stock has demonstrated sustained upward momentum over recent months, gaining 6.18% over the past one month and 40.21% over the trailing three months, according to Massive/Polygon data. On a twelve-month basis, TMO has appreciated 13.83%, underperforming the broader market but maintaining a positive trajectory. The stock currently trades well above both its 50-day moving average of $590.90 and its 200-day moving average of $527.90, indicating a firmly established uptrend. The 14-day relative strength index stands at 62.0, suggesting moderate bullish momentum without entering overbought territory. TMO carries a beta of 0.902, indicating slightly lower volatility relative to the broader market. Average daily trading volume stands at approximately 2.05 million shares, reflecting consistent institutional participation.
Thermo Fisher Scientific Inc. currently carries a market capitalization of approximately $219.4 billion, positioning it among the largest companies in the Healthcare sector, per SID market data. The stock trades at a price-to-earnings ratio of 33.30, reflecting a premium valuation relative to broader market averages and suggesting investors are pricing in sustained earnings growth expectations. However, the PEG ratio stands at an elevated 577.17, according to SEC filings, indicating that the current P/E multiple significantly exceeds near-term earnings growth projections. The price-to-book ratio registers at 4.29, consistent with a capital-light, high-margin life sciences business model. Thermo Fisher offers a modest dividend yield of approximately 0.29%, signaling that the company prioritizes reinvestment and share repurchases over income distribution. Taken together, these valuation metrics position TMO at a premium to the Healthcare sector, reflecting its market leadership in scientific instrumentation and laboratory services.
Thermo Fisher Scientific Inc. registers a composite smart money score of 54, reflecting a neutral overall signal, per SID market data. Institutional ownership scores a perfect 25 out of 25, indicating maximum conviction from large fund managers and sustained accumulation patterns evident in 13F institutional filings. Congressional trading activity scores 11.2 out of 25, suggesting moderate engagement from lawmakers holding positions in the Healthcare sector. Dark pool activity registers at 8.5 out of 25, pointing to below-average off-exchange block trading in recent periods. Insider sentiment presents a notable divergence, scoring just 9.7 out of 25. According to SEC Form 4 filings, there have been 20 insider transactions over the past 90 days, comprising only 2 purchases against 18 sales. This pronounced selling pattern among corporate insiders contrasts sharply with the strong institutional conviction. The imbalance between insider dispositions and institutional accumulation warrants monitoring as a potential divergence signal for near-term price direction.
Thermo Fisher Scientific Inc. has delivered consecutive earnings beats in its two most recently reported quarters, according to company earnings reports. In the quarter reported on April 23, 2026, the company posted earnings per share of $5.44 against a consensus estimate of $5.23, representing a positive surprise of $0.21 or approximately 4.0%. The subsequent quarter reported on July 23 showed further acceleration, with actual EPS of $6.03 exceeding the $5.71 estimate by $0.32, a beat of roughly 5.6%. Looking ahead, analyst estimates project EPS of $5.71 for the quarter with results expected on July 22, and $6.41 for the period ending October 21, per consensus analyst estimates. The sequential improvement in beat magnitude suggests strengthening operational execution. The upward trajectory in estimated earnings from $5.71 to $6.41 reflects anticipated seasonal strength and potential margin expansion across the company's laboratory products and services portfolio.
Wall Street analyst sentiment on Thermo Fisher Scientific Inc. leans constructively positive, according to SID consensus data. In the most recent coverage action dated September 3, 2026, CLSA initiated coverage with an Outperform rating, adding a new bullish voice to the analyst community, per Wall Street analyst reports. Morgan Stanley maintained its Overweight rating on July 27, reaffirming confidence in the company's growth trajectory following the earnings beat. Barclays similarly reiterated an Overweight rating on July 24, aligning with the post-earnings positive sentiment. On the neutral side, Piper Sandler maintained its Neutral stance on July 27, while RBC Capital held its Sector Perform rating on July 24. Among the five most recent analyst actions, three carry bullish designations (Outperform or Overweight) and two reflect neutral positioning, resulting in a 60% bullish skew. No analysts among recent coverage updates have issued bearish or underperform ratings on the stock, indicating an absence of notable downside conviction.
The latest Smart Investors Daily articles mentioning TMO.
